High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease

C. H. Weaver, Lee Schwartzberg, W. Li, B. Hazelton, W. West

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

This paper evaluates a comprehensive strategy of chemotherapy mobilization of peripheral blood progenitor cells (PBPCs) followed by high-dose chemotherapy for the treatment of refractory or relapsed Hodgkin's disease (HD). Patients with relapsed or refractory HD were enrolled to receive cyclophosphamide, etoposide ± cisplatin (CE ± P) and rhG-CSF mobilization of PBPCs. Patients achieving ≤ 2.5 x 106 CD34+ cells/kg following initial mobilization were eligible to receive a second course of CE ± P. Unmanipulated PBPCs alone were infused following administration of high-dose carmustine, etoposide, cytarabine arabinoside and cyclophosphamide (BEAC). Thirty-eight consecutive patients with relapsed or refractory HD were initially enrolled to receive CE ± P. Analysis was performed on an intent-to-treat basis. A median of 6.4 x 106 CD34+ cells/kg (range 0.66-62.3) were collected with a median of 3 (range 2-9) leukaphereses. Twenty-eight of 38 (74%) patients achieved ≥ 2.5 x 106 CD34+ cells/kg. Analysis of variables potentially effecting mobilization of CD34+ cells revealed that only the amount of prior chemotherapy statistically influenced collecting CD34+ cells (P = 0.005). Two of six patients undergoing a second mobilization procedure achieved ≥ 2.5 x 106 CD34+ cells/kg for a total of 30 patients eligible to proceed with high-dose BEAC. The 3-year Kaplan-Meier estimate of overall survival (OS) and progression-free survival (PFS) for all 38 patients is 65 and 53%, respectively. The 3-year OS and PFS for the 28 patients receiving BEAC is 77 and 64% respectively vs 33 and 30% for the 10 patients not receiving BEAC, The strategy of CE ± P and BEAC was well tolerated with a 100-day treatment-related mortality of 3.6%. All patients experienced rapid and sustained hematologic recovery with PBPCs alone. The median time to an ANC ≥ 5 x 109/l and platelet transfusion independence was 10 days. Although development of better strategies to mobilize PBPCs may benefit additional patients, currently the best strategy to collect PBPCs is early before patients have received extensive chemotherapy treatment. Collection of PBPCs immediately following initial relapse or induction failure using CE ± P for PBPC mobilization allows sufficient PBPCs to be collected in greater than 90% of patients. Treatment of refractory or relapsed HD utilizing a strategy of CE ± P PBPC mobilization for hematopoietic reconstitution following high-dose BEAC is associated with acceptable toxicity and rapid engraftment. A 3-year PFS greater than 60% can be achieved in the community hospital setting.

Original languageEnglish (US)
Pages (from-to)715-721
Number of pages7
JournalBone Marrow Transplantation
Volume17
Issue number5
StatePublished - May 1 1996

Fingerprint

Hodgkin Disease
Blood Cells
Stem Cells
Transplants
Drug Therapy
Etoposide
Cyclophosphamide
Cisplatin
Therapeutics
Disease-Free Survival
Leukapheresis
Carmustine
Platelet Transfusion
Survival
Cytarabine
Community Hospital
Kaplan-Meier Estimate

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease. / Weaver, C. H.; Schwartzberg, Lee; Li, W.; Hazelton, B.; West, W.

In: Bone Marrow Transplantation, Vol. 17, No. 5, 01.05.1996, p. 715-721.

Research output: Contribution to journalArticle

@article{33a132e0f1e244a3be13c13a1b99e0a9,
title = "High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease",
abstract = "This paper evaluates a comprehensive strategy of chemotherapy mobilization of peripheral blood progenitor cells (PBPCs) followed by high-dose chemotherapy for the treatment of refractory or relapsed Hodgkin's disease (HD). Patients with relapsed or refractory HD were enrolled to receive cyclophosphamide, etoposide ± cisplatin (CE ± P) and rhG-CSF mobilization of PBPCs. Patients achieving ≤ 2.5 x 106 CD34+ cells/kg following initial mobilization were eligible to receive a second course of CE ± P. Unmanipulated PBPCs alone were infused following administration of high-dose carmustine, etoposide, cytarabine arabinoside and cyclophosphamide (BEAC). Thirty-eight consecutive patients with relapsed or refractory HD were initially enrolled to receive CE ± P. Analysis was performed on an intent-to-treat basis. A median of 6.4 x 106 CD34+ cells/kg (range 0.66-62.3) were collected with a median of 3 (range 2-9) leukaphereses. Twenty-eight of 38 (74{\%}) patients achieved ≥ 2.5 x 106 CD34+ cells/kg. Analysis of variables potentially effecting mobilization of CD34+ cells revealed that only the amount of prior chemotherapy statistically influenced collecting CD34+ cells (P = 0.005). Two of six patients undergoing a second mobilization procedure achieved ≥ 2.5 x 106 CD34+ cells/kg for a total of 30 patients eligible to proceed with high-dose BEAC. The 3-year Kaplan-Meier estimate of overall survival (OS) and progression-free survival (PFS) for all 38 patients is 65 and 53{\%}, respectively. The 3-year OS and PFS for the 28 patients receiving BEAC is 77 and 64{\%} respectively vs 33 and 30{\%} for the 10 patients not receiving BEAC, The strategy of CE ± P and BEAC was well tolerated with a 100-day treatment-related mortality of 3.6{\%}. All patients experienced rapid and sustained hematologic recovery with PBPCs alone. The median time to an ANC ≥ 5 x 109/l and platelet transfusion independence was 10 days. Although development of better strategies to mobilize PBPCs may benefit additional patients, currently the best strategy to collect PBPCs is early before patients have received extensive chemotherapy treatment. Collection of PBPCs immediately following initial relapse or induction failure using CE ± P for PBPC mobilization allows sufficient PBPCs to be collected in greater than 90{\%} of patients. Treatment of refractory or relapsed HD utilizing a strategy of CE ± P PBPC mobilization for hematopoietic reconstitution following high-dose BEAC is associated with acceptable toxicity and rapid engraftment. A 3-year PFS greater than 60{\%} can be achieved in the community hospital setting.",
author = "Weaver, {C. H.} and Lee Schwartzberg and W. Li and B. Hazelton and W. West",
year = "1996",
month = "5",
day = "1",
language = "English (US)",
volume = "17",
pages = "715--721",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease

AU - Weaver, C. H.

AU - Schwartzberg, Lee

AU - Li, W.

AU - Hazelton, B.

AU - West, W.

PY - 1996/5/1

Y1 - 1996/5/1

N2 - This paper evaluates a comprehensive strategy of chemotherapy mobilization of peripheral blood progenitor cells (PBPCs) followed by high-dose chemotherapy for the treatment of refractory or relapsed Hodgkin's disease (HD). Patients with relapsed or refractory HD were enrolled to receive cyclophosphamide, etoposide ± cisplatin (CE ± P) and rhG-CSF mobilization of PBPCs. Patients achieving ≤ 2.5 x 106 CD34+ cells/kg following initial mobilization were eligible to receive a second course of CE ± P. Unmanipulated PBPCs alone were infused following administration of high-dose carmustine, etoposide, cytarabine arabinoside and cyclophosphamide (BEAC). Thirty-eight consecutive patients with relapsed or refractory HD were initially enrolled to receive CE ± P. Analysis was performed on an intent-to-treat basis. A median of 6.4 x 106 CD34+ cells/kg (range 0.66-62.3) were collected with a median of 3 (range 2-9) leukaphereses. Twenty-eight of 38 (74%) patients achieved ≥ 2.5 x 106 CD34+ cells/kg. Analysis of variables potentially effecting mobilization of CD34+ cells revealed that only the amount of prior chemotherapy statistically influenced collecting CD34+ cells (P = 0.005). Two of six patients undergoing a second mobilization procedure achieved ≥ 2.5 x 106 CD34+ cells/kg for a total of 30 patients eligible to proceed with high-dose BEAC. The 3-year Kaplan-Meier estimate of overall survival (OS) and progression-free survival (PFS) for all 38 patients is 65 and 53%, respectively. The 3-year OS and PFS for the 28 patients receiving BEAC is 77 and 64% respectively vs 33 and 30% for the 10 patients not receiving BEAC, The strategy of CE ± P and BEAC was well tolerated with a 100-day treatment-related mortality of 3.6%. All patients experienced rapid and sustained hematologic recovery with PBPCs alone. The median time to an ANC ≥ 5 x 109/l and platelet transfusion independence was 10 days. Although development of better strategies to mobilize PBPCs may benefit additional patients, currently the best strategy to collect PBPCs is early before patients have received extensive chemotherapy treatment. Collection of PBPCs immediately following initial relapse or induction failure using CE ± P for PBPC mobilization allows sufficient PBPCs to be collected in greater than 90% of patients. Treatment of refractory or relapsed HD utilizing a strategy of CE ± P PBPC mobilization for hematopoietic reconstitution following high-dose BEAC is associated with acceptable toxicity and rapid engraftment. A 3-year PFS greater than 60% can be achieved in the community hospital setting.

AB - This paper evaluates a comprehensive strategy of chemotherapy mobilization of peripheral blood progenitor cells (PBPCs) followed by high-dose chemotherapy for the treatment of refractory or relapsed Hodgkin's disease (HD). Patients with relapsed or refractory HD were enrolled to receive cyclophosphamide, etoposide ± cisplatin (CE ± P) and rhG-CSF mobilization of PBPCs. Patients achieving ≤ 2.5 x 106 CD34+ cells/kg following initial mobilization were eligible to receive a second course of CE ± P. Unmanipulated PBPCs alone were infused following administration of high-dose carmustine, etoposide, cytarabine arabinoside and cyclophosphamide (BEAC). Thirty-eight consecutive patients with relapsed or refractory HD were initially enrolled to receive CE ± P. Analysis was performed on an intent-to-treat basis. A median of 6.4 x 106 CD34+ cells/kg (range 0.66-62.3) were collected with a median of 3 (range 2-9) leukaphereses. Twenty-eight of 38 (74%) patients achieved ≥ 2.5 x 106 CD34+ cells/kg. Analysis of variables potentially effecting mobilization of CD34+ cells revealed that only the amount of prior chemotherapy statistically influenced collecting CD34+ cells (P = 0.005). Two of six patients undergoing a second mobilization procedure achieved ≥ 2.5 x 106 CD34+ cells/kg for a total of 30 patients eligible to proceed with high-dose BEAC. The 3-year Kaplan-Meier estimate of overall survival (OS) and progression-free survival (PFS) for all 38 patients is 65 and 53%, respectively. The 3-year OS and PFS for the 28 patients receiving BEAC is 77 and 64% respectively vs 33 and 30% for the 10 patients not receiving BEAC, The strategy of CE ± P and BEAC was well tolerated with a 100-day treatment-related mortality of 3.6%. All patients experienced rapid and sustained hematologic recovery with PBPCs alone. The median time to an ANC ≥ 5 x 109/l and platelet transfusion independence was 10 days. Although development of better strategies to mobilize PBPCs may benefit additional patients, currently the best strategy to collect PBPCs is early before patients have received extensive chemotherapy treatment. Collection of PBPCs immediately following initial relapse or induction failure using CE ± P for PBPC mobilization allows sufficient PBPCs to be collected in greater than 90% of patients. Treatment of refractory or relapsed HD utilizing a strategy of CE ± P PBPC mobilization for hematopoietic reconstitution following high-dose BEAC is associated with acceptable toxicity and rapid engraftment. A 3-year PFS greater than 60% can be achieved in the community hospital setting.

UR - http://www.scopus.com/inward/record.url?scp=0029922686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029922686&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 715

EP - 721

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -